A Phase II randomized double-blind study of the | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

15 participants needed

1 Location

Brief description of study

This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian cancer, however no drug has been approved for maintenance therapy in recurrent endometrial cancer by the FDA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: endometrial cancer
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 832490

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study